A phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil and oxaliplatin (modified FOLFOX-6) in patients with metastatic pancreatic cancer.
M. J. Pishvaian
No relevant relationships to disclose
R. Slack
No relevant relationships to disclose
A. Witkiewicz
No relevant relationships to disclose
A. R. He
No relevant relationships to disclose
J. J. Hwang
No relevant relationships to disclose
A. Hankin
No relevant relationships to disclose
L. Ley
No relevant relationships to disclose
S. K. Apte
No relevant relationships to disclose
S. J. Littman
No relevant relationships to disclose
L. M. Weiner
No relevant relationships to disclose
J. Marshall
No relevant relationships to disclose
J. R. Brody
No relevant relationships to disclose